GGHC
JAZZ icon

Gilder Gagnon Howe & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-35,240
Closed -$4.46M – 274
2013
Q4 		$4.46M Buy
+35,240
New +$3.65M 0.06% 156

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Gilder Gagnon Howe & Co's JAZZ Position: Q1 2014 in Review

Gilder Gagnon Howe & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2014, closing a stake of 35,240 shares — an estimated $4.46M sold.

Gilder Gagnon Howe & Co first reported a position in JAZZ in Q4 2013 and held it in 1 quarter. The position peaked at $4.46M in Q4 2013. 318 funds tracked by Wall St. Rank hold JAZZ as of Q1 2014.

  • Gilder Gagnon Howe & Co reported no remaining Jazz Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 35,240 Jazz Pharmaceuticals shares in Q1 2014, an estimated $4.46M.
  • Gilder Gagnon Howe & Co first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Jazz Pharmaceuticals position peaked at $4.46M in Q4 2013.
  • 318 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2014.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2014, filed 9 May 2014.